Document:

Exhibit

 Exhibit 10.1
2017 Cash Incentive Compensation Plan

Eligible Employees:  All non-Section 16 officers (“Vice Presidents”) and senior executives (Section 16) officers (“Executive Officers”) of the Company are eligible for participation in the Company’s 2017 Cash Incentive Compensation Plan.  

Applicable Period:  The 2017 Cash Incentive Plan applies to performance during the Company’s fiscal year ending December 31, 2017.  

 Components of the Plan and Criteria to Fund:  The 2017 Cash Incentive Compensation Plan consists of the following three components: (i) revenue targets; (ii) EBITDA targets, and (iii) achievement of commercial channel efficiencies.  Each component of the 2017 Cash Incentive Compensation Plan includes targets at minimum, plan, and maximum payout. The minimum targets serve as the threshold upon which the incentive pool will begin to fund for that component.  Achievement of the components at plan/target will earn the target cash incentive opportunity.  Payout will be calculated along a linear continuum from minimum to plan/target and from plan/target to maximum with the maximum target serving as the point at which the management team will earn the highest possible cash incentive opportunity.

The minimum performance target must be met in order for a portion of the bonus to be paid relative to any one of the three components.  Each component will be measured separately.  Bonus payouts will be based forty percent (40%) on achievement of revenue targets, forty percent (40%) on achievement of EBITDA targets; and twenty percent (20%) on achievement of commercial channel efficiencies.

The following table below represents the target bonus and maximum bonus for each of the Company’s Vice Presidents and above and as a percent of such employee’s annual base salary.  

	
				
	Executive Officer

	Target
	Maximum

	President and CEO
	125%
	175%

	Executive Officers (other than President and CEO)
	75%
	100%

	Vice Presidents
	50%
	70%Exhibit

Exhibit 10.2
2017 Annual Equity Incentive Plan

The 2017 Annual Equity Incentive Plan provides for the issuance of equity incentive awards in the form of (i) non-qualified stock options; (ii) time-based restricted stock units; and (iii) performance-based restricted stock units.

	
				
	Executive Officer
	Time-Based Restricted Stock Units 
(# shares)
	Performance-Based Restricted Stock Units 
(# shares)
	Non-Qualified Stock Options (# shares)

	Douglas C. Bryant
President and Chief Executive Officer
	20,250
	20,249
	40,499

	Michael D. Abney, Jr.
Senior Vice President, Distribution
	7,172
	7,171
	14,343

	Robert J. Bujarski
Senior Vice President, Business Development and General Counsel
	7,172
	7,171
	14,343

	Werner Kroll
Senior Vice President, Research and Development
	7,172
	7,171
	14,343

	Edward K. Russell
Senior Vice President, Global Commercial Operations
	7,172
	7,171
	14,343

	Randall J. Steward
Chief Financial Officer
	7,594
	7,593
	15,187

The vesting period for the non-qualified stock is over four years with the first 50% of such option awards vesting at the end of the second-year anniversary of the grant date and the remainder vesting 25% annually on each of the following two anniversaries thereafter.    

The vesting period for the time-based restricted stock units is 100% of such equity awards vesting at the end of the four-year anniversary of the grant date.    

The vesting for the performance based restricted stock units (PSUs) is over a three year time period and is tied to the achievement of net revenue growth targets.  If the net revenue targets are achieved, then the PSUs will vest 100% upon the third anniversary of the Equity Grant Date.  If the company has not achieved the annual net revenue growth targets at the end of the three year period, the PSUs will be canceled.  The PSUs may vest early upon early achievement of the three year net revenue growth targets.  The net revenue calculation will be adjusted for influenza revenue volatility.Exhibit

 Exhibit 10.3
2017 Annual Base Salaries

	
			
	Executive Officer
	Prior Base Salary
	2017 Base Salary

	Douglas C. Bryant
President and Chief Executive Officer
	$558,846
	$574,846

	Michael D. Abney, Jr.
Senior Vice President, Distribution
	$334,780
	$352,780

	Robert J. Bujarski
Senior Vice President, Business Development and General Counsel
	$362,759
	$372,759

	Werner Kroll
Senior Vice President, Research and Development
	$350,127
	$372,000

	Edward K. Russell
Senior Vice President, Global Commercial Operations
	$362,708
	$372,708

	Randall J. Steward
Chief Financial Officer
	$365,058
	$375,058EX-10.17

 Exhibit 10.17 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
 

Inspiring Science 
 Amendment to SGD-1006 

Commercial Supply Agreement executed on 1 December 2010. 

[*] Manufacturing Controls Price Increase 

27 August 2013 
 Vaughn Himes 

VP, Manufacturing 
 21823- 30th Drive S.E. 

Bothell, WA 98021 
 Dear Vaughn: 

Based on the recent Safebridge assessment of SGD-1006 and SGD-1010 occupation exposure level (OEL), a [*]classification has been applied to these molecules.
This change in classification will require additional manufacturing containment and precautions for these [*]. 
 This letter serves to amend the SGD-1006
pricing outlined in the supply agreement executed on 1 December 2010. The purpose of this costing revision is to capture the additional time and materials required to manufacture SGD-1006 [*]. 

[*] implementation will require extended suite time, additional materials, and FTEs. It is estimated that the implementation will result in a cost increase of
[*]. Based on this assessment Seattle Genetics have agreed to increase payment for the [*]. The revised price per gram is outlined in the table below: 

Revised SGD-1006 Pricing Schedule: 
  

							
	SG6 Quantity (g)	 	Current Price ($)/g	 	Batch Cost Increase	 	Revised Cost/g
	[*]	 	[*]	 	[*]	 	[*]

 [*] 

 

Inspiring Science 
 IN WITNESS WHEREOF, the parties have executed this Amendment, effective as of the Amendment Effective
Date. 
 Agreed and Accepted: 
  

									
	SAFC, Inc.	 		 	Seattle Genetics, Inc.
					
	By:	 	 /s/ Gills Cotter
	 		 	By:	 	 /s/ Clay B. Siegall

					
	Name:	 	 Gills Cotter
	 		 	Name:	 	 Clay B. Siegall

					
	Title:	 	 President
	 		 	Title:	 	 President and CEO

					
	Date:	 	 December 15, 2014
	 		 	Date:	 	 January 20, 2014EX-10.18

 Exhibit 10.18 
  

			
	

	  	3050 Spruce Street
	  	St. Louis, MO 63103
	  	Tel (800) 448-0471
	  	Fax (314) 286-7817
	  	www.safcglobal.net

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately
with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
 Second Amendment
to SGD-1006 
 Commercial Supply Agreement executed on 1 December 2010 and 

First Amendment to Commercial Supply Agreement executed on 

20 January 2014 (the “First Amendment”)(the Commercial Supply 

Agreement together with the First Amendment, the “Supply Agreement”) 

19 September 2016 
 Vaughn Himes 

21823 30th Drive S.E. 

Bothell, WA 98021 
 Dear Vaughn 

This letter agreement (the “Second Amendment”) confirms the Parties’ agreement to amend the Supply Agreement to change the price per gram/per
Batch (the “Price”) for SGD 1006 set forth in Appendix C to the Supply Agreement. The purpose of the pricing revision is to a) capture the cost of the [*] used in the manufacture of SGD-1006, b) capture the operational efficiencies gained
during the manufacturing of the [*] c) capture the increased labor and overhead costs in the [*], and d) capture the [*] inventory remaining from production [*]. Beginning as of January 1, 2017, certain [*], as listed in the second table below,
that were previously provided [*] in accordance with cGMP, Applicable Laws and the Quality Agreement, and the [*]. Through 2016, these [*] had been provided by or purchased separately by [*]. In addition, effective as of January 1, 2017, any
[*] from each batch production will now be owned by [*]. 
 The table below compares the current price per gram under the First Amendment with the Price per
gram effective as of the Effective Date of this Second Amendment. 
  

					
	 SGD-1006 - 300 gm batch
	  	Price per gm	 
	 First Amendment to Commercial Supply Agreement executed on 20 January 2014
	  	 	[*]	 
	 Second Amendment to Commercial Supply Agreement
	  	 	[*]	 

  
  

 

			
	CONFIDENTIAL	 	Page1 of 3

 

 
  
  

The table below itemizes the components of the amended Price. 

[*] 
  

 
 In addition to the [*] in this Second Amendment, SAFC
and Seattle Genetics agree to perform an analysis of the [*] prior to discussing any change to the Price for 2018 to further [*]. 
 The Price as set forth
in this Second Amendment shall be effective as of the first date of Manufacture of the [*]. 
 Terms capitalized, but not defined, herein shall have the
meaning ascribed to them in the Supply Agreement. This Second Amendment shall be effective as of the date of the last signature below (the “Effective Date”). Except as set forth in this Second Amendment, all of the terms and conditions of
the Supply Agreement remain in full force and effect. 
  
  

			
	CONFIDENTIAL	 	Page 2 of 3

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately
with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 

 
 IN WITNESS WHEREOF, the parties have executed this Second amendment by their duly authorized representatives, effective as
of the Effective Date. 
 Agreed and accepted: 
  

									
	SAFC, INC	 		 	SEATTLE GENETICS, INC.
					
	By	 	 /s/ Mike Smith
	 		 	By	 	 /s/ Vaughn B. Himes

					
	Name	 	 Mike Smith
	 		 	Name	 	 Vaughn B. Himes

					
	Title	 	 Site Director
	 		 	Title	 	 EVP

					
	Date	 	 November 22, 2016
	 		 	Date	 	 December 2, 2016

  

			
	CONFIDENTIAL	 	Page 3 of 3

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately
with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}]]